Arkolith/Insider Trading/RXDX/Form 4

Marshall Keith W

Chief Financial OfficerPrometheus Biosciences, Inc. (RXDX) · full profile →Form 4 · filed Jun 16, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
1 non-derivative · 7 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 16, 2023Disposed to issuer(D)88K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 16, 2023Disposed to issuer(D)34K——0
Jun 16, 2023Disposed to issuer(D)13K——0
Jun 16, 2023Disposed to issuer(D)87K——0
Jun 16, 2023Disposed to issuer(D)102K——0
Jun 16, 2023Disposed to issuer(D)136K——0
Jun 16, 2023Disposed to issuer(D)93K——0
Jun 16, 2023Disposed to issuer(D)53K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-015754) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML